Yet more conjugates enter the clinic
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Chimerix's cancer transformation
US approval could mark the company's graduation to oncology.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Private US biotechs head for human trials
Halda, Accent and Vividion take more projects into phase 1.
